Andelyn Biosciences Inc., a patient-focused cell and gene therapy Contract Development and Manufacturing Organization (CDMO), has partnered with Amplo Biotechnology, a pioneer in adeno-associated virus (AAV) regenerative medicines for neuromuscular junction (NMJ) affecting conditions, to provide scalable manufacturing of clinical-grade AAV material leveraging Andelyn’s suspension AAV Curator platform. Diseases of the NMJ typically result in muscle weakness with severe cases requiring the use ...